522 related articles for article (PubMed ID: 32585617)
1. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
[TBL] [Abstract][Full Text] [Related]
2. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.
Lucchini M; Bianco A; Del Giacomo P; De Fino C; Nociti V; Mirabella M
Mult Scler Relat Disord; 2020 Sep; 44():102323. PubMed ID: 32593961
[TBL] [Abstract][Full Text] [Related]
3. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab and Other CD20
Gelfand JM; Cree BAC; Hauser SL
Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
[TBL] [Abstract][Full Text] [Related]
5. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
6. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES; Pretzsch R; Weber MS
Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
8. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
9. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
Zabalza A; Arrambide G; Tagliani P; Cárdenas-Robledo S; Otero-Romero S; Esperalba J; Fernandez-Naval C; Trocoli Campuzano J; Martínez Gallo M; Castillo M; Bonastre M; Resina Sallés M; Beltran J; Carbonell-Mirabent P; Rodríguez-Barranco M; López-Maza S; Melgarejo Otálora PJ; Ruiz-Ortiz M; Pappolla A; Rodríguez Acevedo B; Midaglia L; Vidal-Jordana A; Cobo-Calvo A; Tur C; Galán I; Castilló J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105687
[TBL] [Abstract][Full Text] [Related]
10. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
Maillart E; Papeix C; Lubetzki C; Roux T; Pourcher V; Louapre C
Mult Scler Relat Disord; 2020 Nov; 46():102482. PubMed ID: 32916509
[TBL] [Abstract][Full Text] [Related]
11. Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab.
Thornton JR; Harel A
Mult Scler Relat Disord; 2020 Sep; 44():102341. PubMed ID: 32622338
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Front Immunol; 2021; 12():763412. PubMed ID: 34804051
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy.
Schulte EC; Sellner J
EBioMedicine; 2021 Nov; 73():103635. PubMed ID: 34656879
[No Abstract] [Full Text] [Related]
14. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
15. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.
Flores-Gonzalez RE; Hernandez J; Tornes L; Rammohan K; Delgado S
Mult Scler Relat Disord; 2021 Apr; 49():102777. PubMed ID: 33508573
[TBL] [Abstract][Full Text] [Related]
16. Therapies for multiple sclerosis targeting B cells.
Milo R
Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
[TBL] [Abstract][Full Text] [Related]
17. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
19. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
[TBL] [Abstract][Full Text] [Related]
20. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
